|RDHL -- Israel Stock|| |
ILS 325.80 14.60 4.69%
The latest increase in of RedHill Biopharma short term price appreciation has created some momentum for investors as it was traded today as low as 311.2
and as high as 325.8
per share. The company directors and management have been quite successful with maneuvering the fund at opportune times to take advantage of all market conditions in February
. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 4.7778. This high volatility is attributed to the latest market swings and not so good earning reports for some of the RedHill Biopharma partners. This diagnostics interface makes it easy to digest most current publicly released information about RedHill Biopharma as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis RedHill Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency. Additionally take a look at Your Equity Center
RedHill Biopharma Note
The company recorded loss per share of 0.17. RedHill Biopharma had not issued any dividends in recent years. RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 75 people. To find out more about REDHILL BIOPHARMA contact Ori Shilo at 972 3 541 3131 or learn more at http://www.redhillbio.com.
RedHill Biopharma Alerts
|RedHill Biopharma is not yet fully synchronised with the market data|
|RedHill Biopharma has very high historical volatility over the last 30 days|
|The company reported revenue of 8.36M. Net Loss for the year was (38.82M) with profit before overhead, payroll, taxes, and interest of 5.52M. |
|REDHILL BIOPHARMA has accumulated about 53.19M in cash with (34.46M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. |
The company currently falls under 'Small-Cap' category with current market capitalization of 876.59M.
RedHill Biopharma has return on total asset (ROA) of (41.05) %
which means that it has lost $41.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (80.66) %
meaning that it generated substantial loss on money invested by shareholders.
RedHill Biopharma Technical and Predictive Indicators